Aldeyra Therapeutics, Inc. (ALDX)
| Market Cap | 290.60M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -44.80M |
| Shares Out | 59.55M |
| EPS (ttm) | -0.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 403,133 |
| Open | 4.810 |
| Previous Close | 4.860 |
| Day's Range | 4.790 - 5.020 |
| 52-Week Range | 2.710 - 6.550 |
| Beta | 1.37 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+104.92%) |
| Earnings Date | Nov 7, 2024 |
About ALDX
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ALDX stock is "Strong Buy." The 12-month stock price forecast is $10.0, which is an increase of 104.92% from the latest price.
News
Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug...
Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects
Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. AbbVie entered an option agreement with Aldeyra, potentially licensing reproxalap for global markets. Al...
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership
Aldeyra Therapeutics' Reproxalap eye drop for Dry Eye Disease has new positive data for the second NDA attempt. Aldeyra has an option agreement with AbbVie, potentially leading to significant mileston...
Aldeyra's New Eye Drug Shows Positive Results In FDA-Approved Study, Stock Jumps Over 30%
Aldeyra Therapeutics Inc.'s ALDX Phase 3 dry eye chamber clinical trial of 0.25% reproxalap ophthalmic solution achieves the primary endpoint.
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, August 8, 2024, at 9:00 a.m. (ET) to prov...
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics to Host Investor Roundtable Q&A
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra: A Speculative Buy Amid Reproxalap's NDA Resubmission
Aldeyra Therapeutics offers a high-risk/high-reward investment opportunity with its Reproxalap program and promising pipeline beyond Reproxalap. Reproxalap has shown positive results in preclinical an...
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and ...
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to p...
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and ...
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie
Lead asset, reproxalap, has clear path to regulatory approval in Dry Eye Disease. Option deal for commercial license with AbbVie signed - $400M in milestones, 60/40 profit shares of US market and tier...
Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated dise...
Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects
Aldeyra Therapeutics is a biotech company focused on developing treatments for immune-mediated inflammatory diseases, with its leading drug candidate being Reproxalap for dry eye and allergic conjunct...
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...